MARKET

FPRX

FPRX

Five Prime
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.490
+0.290
+6.90%
Closed 16:41 09/25 EDT
OPEN
4.180
PREV CLOSE
4.200
HIGH
4.620
LOW
4.180
VOLUME
348.30K
TURNOVER
--
52 WEEK HIGH
7.34
52 WEEK LOW
1.750
MARKET CAP
164.46M
P/E (TTM)
-1.5115
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Benzinga's Top Upgrades, Downgrades For September 22, 2020
Upgrades * According to Guggenheim, the prior rating for Five Prime Therapeutics Inc (NASDAQ: FPRX) was changed from Neutral to Buy. For the second quarter, Five Prime Therapeutics had an EPS of $0.48, compared to year-ago quarter EPS of $0.99. At the moment, the stock has a 52-week-high of $7.34 and
Benzinga · 5d ago
Five Prime Therapeutics (FPRX) Presents At Wells Fargo Securities 2020 Virtual Healthcare Conference - Slideshow
The following slide deck was published by Five Prime Therapeutics, Inc. in conjunction with this event.
Seekingalpha · 09/11 21:39
Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference
Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference
Business Wire · 09/09 23:30
Five Prime Therapeutics EPS beats by $0.22, misses on revenue
Five Prime Therapeutics (NASDAQ:FPRX): Q2 GAAP EPS of -$0.48 beats by $0.22. Revenue of $3.42M (+2.7% Y/Y) misses by $1.93M. Press Release
seekingalpha · 08/07 01:30
Five Prime Therapeutics (FPRX) Reports Q2 Loss, Misses Revenue Estimates
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 31.43% and -22.76%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/07 00:30
Five Prime Therapeutics Reports Second Quarter 2020 Results
Five Prime Therapeutics Reports Second Quarter 2020 Results
Business Wire · 08/06 20:05
Five Prime Therapeutics (FPRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
Five Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Five Prime Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Business Wire · 07/29 23:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FPRX. Analyze the recent business situations of Five Prime through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FPRX stock price target is 8.83 with a high estimate of 11.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 150
Institutional Holdings: 27.89M
% Owned: 76.16%
Shares Outstanding: 36.63M
TypeInstitutionsShares
Increased
30
3.09M
New
32
214.49K
Decreased
33
1.37M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
President/Chief Executive Officer
Thomas Civik
Chief Financial Officer/Executive Vice President
David Smith
Executive Vice President
Helen Collins
Secretary
Francis Sarena
Independent Director
Franklin Berger
Independent Director
Kapil Dhingra
Independent Director
Peder Jensen
Independent Director
Lori Lyons-Williams
Independent Director
Garry Nicholson
Independent Director
Carol Schafer
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FPRX
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company’s pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Five Prime Therapeutics Inc stock information, including NASDAQ:FPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FPRX stock methods without spending real money on the virtual paper trading platform.